Will Element Bio DESTROY Illumina stock?
Overall Thesis
Element Biosciences' AVITI machine offers dramatically better total cost of ownership than Illumina's NovaSeq (7x cheaper year-one) and competitive pricing vs NextSeq, while the decentralization trend toward hospital-based turnkey genomics labs favors element's desktop platform; Illumina stock is in serious trouble unless it embraces new pricing/platform realities.
Narratives
Illumina faces major product and pricing competitive pressure from Element Biosciences AVITI, with total cost of ownership 7x higher for NovaSeq users in year one; decentralization of genomics to hospital turnkey labs favors cheaper desktop sequencers, making Illumina's premium NovaSeq platform increasingly unsellable.
Key Arguments
- AVITI delivers ~$520/GB vs NovaSeq ~$580/GB consumables - cheaper.
- AVITI capex is $289K vs NovaSeq $980K.
- Element's lease option makes year-one cost $380K vs NovaSeq $2.3M.
- Hospital turnkey genomic labs favor cheaper desktop sequencers.
- 100-lab buildout (Quantin's plan) means $60M capex savings vs NextSeq and $20M/year ongoing.
Element Biosciences (private) is set to take massive Illumina market share rapidly with its superior-TCO AVITI platform and clear fit with the industry's decentralization mega-trend.
Key Arguments
- AVITI has lower capex, lower consumable costs, and competitive quality.
- Element's team and execution are underrated.
- Decentralization to hospital labs amplifies the Element advantage.